Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 380 employees. About 70% of the employees and projects are externally funded. Read more
Cancer patients are often shown as stereotypes in the media – a person without hair in a hospital bed. Sigrid S. Skånland wants to change this by showing the diversity of people with cancer through portraits.
Sigrid S. Skånland is a researcher and project leader at the Institute for Cancer Research. She was awarded the “Researcher of the Year” prize in 2023 for the work she does on developing and implementing precision medicine for patients with blood cancer. She has spent the last decade studying patient cells in the lab and says she would like to interact more with the patients.
Researcher Audun Kvalvaag at Department of Molecular Cell Biology (MCB) and Centre for Cancer Cell Reprogramming (CanCell) is a specialist on activation of cytotoxic T cells, and he has recently been involved in collaborations with Elliot Philips in Xiang-Peng Kong´s group at New York University Grossman School of Medicine, and with Pablo Céspedes and Megat Hamid at Chinese Academy of Medical Sciences Oxford Institute, University of Oxford. This has resulted in articles in two highly prestigious immunology journals, Science Immunology and Nature Immunology. Both papers elucidate mechanisms involved in T cell mediated tumour control and may represent novel avenues for immunotherapeutic cancer treatment.
The long-term collaboration between Department of Molecular Cell Biology (Iversen/Sandvig and collaborators) and Department of Tumor Biology (Mælandsmo group) has resulted in a new article published in International Journal of Nanomedicine (impact factor 8.0). Remya Valsalakumari is the first author and Tore-Geir Iversen the last and communicating author. The data show promising results following injection of cabazitaxel-loaded polyalkyl cyanoacrylate nanoparticles in mice bearing patient derived xenografts of triple negative breast cancer. The nanoparticles gave a strong effect both on the tumor and on the tumor-associated myeloid compartment, which probably boost the anti-tumor response.
Cancer Grand Challenges (CGC) is a funding initiative announced every second year that is co-founded by the two largest funders of cancer research in the world - Cancer Research UK and the National Cancer Institute in the US - to come together, think differently and take on some of cancer’s toughest challenges. Five new global teams were recently selected to receive up to $25m (275 mill NOK) each over five years. Johanna Olweus and her research group, the Experimental Immunotherapy Group at the Department of Cancer Immunology, are partners of the MATCHMAKERS team, focussed on deciphering the T-cell receptor cancer-recognition code. This is the first time a Nordic scientist is part of a CGC team, and the news was covered by the Norwegian Broadcasting Corporation (NRK).
At the recent 59th Winter Meeting of the Norwegian Bioscience Society (NBS) at Storefjell Mountaln Resort, Kirsten Sandvig and Tore Skotland from Institute for Cancer Research were announced as new honorary members of NBS. Sandvig and Skotland have successful careers in the biosciences and have contributed importantly to the activities of NBS.
Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman MW, Eder T, Abdallah DI, Maurer B, Wagner C, Schönefeldt S, Spirk K, Pichler A, Pemovska T, Schweicker C, Pölöske D, Hubanic E, Jungherz D, Müller TA, Aung MMK, Orlova A, Pham HTT, Zimmel K, Krausgruber T, Bock Cet al.(2024) Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia J Clin Invest, 134(8) DOI 10.1172/JCI168536, PubMed 38618957
Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S(2024) Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16 J Immunother Cancer, 12(4) DOI 10.1136/jitc-2023-008179, PubMed 38604812
Totland MZ, Knudsen LM, Rasmussen NL, Omori Y, Sørensen V, Elster VCW, Stenersen JM, Larsen M, Jensen CL, Zickfeldt Lade AA, Bruusgaard E, Basing S, Kryeziu K, Brech A, Aasen T, Lothe RA, Leithe E(2024) The E3 ubiquitin ligase ITCH negatively regulates intercellular communication via gap junctions by targeting connexin43 for lysosomal degradation Cell Mol Life Sci, 81(1), 171 DOI 10.1007/s00018-024-05165-8, PubMed 38597989